Analogous results using tissue TMB were reported by Offin et al. (29), claiming that EGFR-mutant lung cancer patients with high TMB had shorter time to treatment discontinuation and OS compared to patients with low/intermediate TMB. Here, EGFR is linked to lung cancer.